|
NSJ Bioreagents
rabbit Rabbit, supplied by NSJ Bioreagents, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/sheep+anti+lyve+1+antibody/pm32640183-334-3-13?v=NSJ+Bioreagents Average 90 stars, based on 1 article reviews
rabbit - by Bioz Stars,
2026-07
90/100 stars
|
Buy from Supplier |
|
Rockland Immunochemicals
secondary antibodies against cd31 Secondary Antibodies Against Cd31, supplied by Rockland Immunochemicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/sheep+anti+lyve+1+antibody/pm27574793-366-39-52?v=Rockland+Immunochemicals Average 90 stars, based on 1 article reviews
secondary antibodies against cd31 - by Bioz Stars,
2026-07
90/100 stars
|
Buy from Supplier |
|
R&D Systems
sheep anti rat lyve1 ![]() Sheep Anti Rat Lyve1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/sheep+anti+lyve+1+antibody/pm37605828-96-47-52?v=R%26D+Systems Average 93 stars, based on 1 article reviews
sheep anti rat lyve1 - by Bioz Stars,
2026-07
93/100 stars
|
Buy from Supplier |
|
R&D Systems
goat anti mouse lyve1 ![]() Goat Anti Mouse Lyve1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/sheep+anti+lyve+1+antibody/pmc04926867-273-26-29?v=R%26D+Systems Average 99 stars, based on 1 article reviews
goat anti mouse lyve1 - by Bioz Stars,
2026-07
99/100 stars
|
Buy from Supplier |
|
R&D Systems
anti mouse lyve1 ![]() Anti Mouse Lyve1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/sheep+anti+lyve+1+antibody/pmc07478896-24-2-7?v=R%26D+Systems Average 94 stars, based on 1 article reviews
anti mouse lyve1 - by Bioz Stars,
2026-07
94/100 stars
|
Buy from Supplier |
|
R&D Systems
rat mab against lyve 1 223322 ag ![]() Rat Mab Against Lyve 1 223322 Ag, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/sheep+anti+lyve+1+antibody/pm31767783-67-0-19?v=R%26D+Systems Average 94 stars, based on 1 article reviews
rat mab against lyve 1 223322 ag - by Bioz Stars,
2026-07
94/100 stars
|
Buy from Supplier |
|
R&D Systems
rat anti lyve 1 ![]() Rat Anti Lyve 1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/sheep+anti+lyve+1+antibody/10__7554_slash_elife__46206-279-29-31?v=R%26D+Systems Average 93 stars, based on 1 article reviews
rat anti lyve 1 - by Bioz Stars,
2026-07
93/100 stars
|
Buy from Supplier |
|
Novus Biologicals
rat anti lyve 1 ![]() Rat Anti Lyve 1, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/sheep+anti+lyve+1+antibody/pmc04753256-163-86-88?v=Novus+Biologicals Average 90 stars, based on 1 article reviews
rat anti lyve 1 - by Bioz Stars,
2026-07
90/100 stars
|
Buy from Supplier |
|
R&D Systems
rat anti lyve1 ![]() Rat Anti Lyve1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/sheep+anti+lyve+1+antibody/pm31369756-62-10-13?v=R%26D+Systems Average 94 stars, based on 1 article reviews
rat anti lyve1 - by Bioz Stars,
2026-07
94/100 stars
|
Buy from Supplier |
|
Santa Cruz Biotechnology
rat anti lymphatic vessel endothelial hyaluronan receptor 1 lyve 1 ![]() Rat Anti Lymphatic Vessel Endothelial Hyaluronan Receptor 1 Lyve 1, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/sheep+anti+lyve+1+antibody/pmc04639986-483-54-69?v=Santa+Cruz+Biotechnology Average 96 stars, based on 1 article reviews
rat anti lymphatic vessel endothelial hyaluronan receptor 1 lyve 1 - by Bioz Stars,
2026-07
96/100 stars
|
Buy from Supplier |
|
OriGene
anti lyve1 ![]() Anti Lyve1, supplied by OriGene, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/sheep+anti+lyve+1+antibody/pm38200313-598-46-50?v=OriGene Average 93 stars, based on 1 article reviews
anti lyve1 - by Bioz Stars,
2026-07
93/100 stars
|
Buy from Supplier |
Image Search Results
Journal: American journal of physiology. Gastrointestinal and liver physiology
Article Title: An optimized visualization and quantitative protocol for in-depth evaluation of lymphatic vessel architecture in the liver.
doi: 10.1152/ajpgi.00139.2023
Figure Lengend Snippet: Figure 2. Three-dimensional (3-D) visualization of lymphatic vessels in the portal tract of normal mouse and human livers. A, left: reconstructed 3-D image of the portal tract in the normal mouse liver. Imaging condition: z-step size ¼ 0.4 μm, image volume [x] [y] [z] ¼ 1,290 μm 1,290 μm 354 μm. Liver tissue was cleared and stained with LYVE1 (red, lymphatic vessel), ASMA (white, portal vein), and CK19 (green, bile duct) antibodies. Right: 3-D volume-rendering image of lymphatic vessels and bile ducts using Imaris software with an enlarged image. Scale bars: 100 μm. B: reconstructed 3-D image of the portal tract in normal human liver tissue. Imaging condition: z-step size ¼ 0.4 μm, image volume [x] [y] [z] ¼ 1,002 μm 1,168 μm 228 μm. Liver tissue was cleared and stained with PDPN (red, lymphatic vessel) and ASMA (white, portal vein) antibodies. Scale bar: 100 μm. C, left: recon- structed 3-D image of the portal tract in normal human liver tissue. Imaging condition: z-step size ¼ 0.4 μm, image volume [x] [y] [z] ¼ 1,193 μm 1,193 μm 233 μm. Liver tissue was cleared and stained with PDPN (red, lymphatic vessel) and CK19 (green, bile duct) antibodies. Right, top: enlarged reconstructed 3-D image. Right, bottom: 3-D volume-rendering image. Scale bars: 100 μm.
Article Snippet: The liver slides were washed with PBS and incubated in blocking buffer (PBS containing 5% donkey serum and 0.3% triton X-100) at room temperature for 1 h. After blocking was completed, the liver slides were incubated with goat anti-mouse LYVE1 (1:200, AF2125, R&D Systems, Minneapolis, MN) (17),
Techniques: Imaging, Staining, Software
Journal: American journal of physiology. Gastrointestinal and liver physiology
Article Title: An optimized visualization and quantitative protocol for in-depth evaluation of lymphatic vessel architecture in the liver.
doi: 10.1152/ajpgi.00139.2023
Figure Lengend Snippet: Figure 3. Lymphatic vessels in the capsular area of normal mouse, rat, and human livers. A: comparison of the capsular areas (thickness) among normal human (n ¼ 4), mouse (n ¼ 7), and rat livers (n ¼ 7) stained with Sirius Red. Scale bars: 100 μm. B: two-dimensional (2-D) conventional histology images of the capsular areas (paraffin section, 7-lm thickness) from normal human, mouse, and rat livers stained with PDPN or LYVE1 (red, lymphatic vessel) and Col-I (green, collagenous capsular area), respectively. Yellow arrows indicate lymphatic vessels inside the Col-I positive capsular area. 2-D images were merged with differential interference contrast (DIC) images. Scale bars: 100 μm. C: surface of human liver tissue (top) covered by thin collagenous cap- sule (Glisson’s capsule, yellow arrowhead, bottom) was isolated from normal human liver tissue to visualize capsular lymphatic vessels. D, left: recon- structed 3-D image of lymphatic vessels (PDPN, red) in the capsular area of normal human liver tissue. Imaging condition: z-step size ¼ 0.3 μm, image volume [x] [y] [z] ¼ 1,551 μm 1,551 μm 145 μm. Scale bars: 100 μm. Right: 3-D volume-rendering image. Scale bars: 100 μm.
Article Snippet: The liver slides were washed with PBS and incubated in blocking buffer (PBS containing 5% donkey serum and 0.3% triton X-100) at room temperature for 1 h. After blocking was completed, the liver slides were incubated with goat anti-mouse LYVE1 (1:200, AF2125, R&D Systems, Minneapolis, MN) (17),
Techniques: Comparison, Staining, Isolation, Imaging
Journal: American journal of physiology. Gastrointestinal and liver physiology
Article Title: An optimized visualization and quantitative protocol for in-depth evaluation of lymphatic vessel architecture in the liver.
doi: 10.1152/ajpgi.00139.2023
Figure Lengend Snippet: Figure 4. Spatial relationship between lymphatic vessels and bile ducts in biliary cirrhotic livers. A: reconstructed three-dimensional (3-D) image of the portal tract in the liver from a sham-operated mouse (EC-GFP reporter mouse). Imaging condition: z-step size ¼ 0.4 μm, image volume [x] [y] [z] ¼ 1,025 μm 1,161 μm 211 μm. Liver tissue was cleared and stained with LYVE1 (red, lymphatic vessel: LV) and CK19 (white, bile duct: BD). Scale bar: 100 μm. B: reconstructed 3-D image of the portal tract in the liver from a 4-wk BDL mouse (EC-GFP reporter mouse) with a representative single optical sec- tion in the right. Imaging condition: z-step size ¼ 0.4 μm, image volume [x] [y] [z] ¼ 862 μm 939 μm 220 μm. Liver tissue was cleared and stained with LYVE1 (red, lymphatic vessel) and CK19 (white, bile duct). LV, lymphatic vessel; BD, bile duct; PV, portal vein; HA, hepatic artery; PBP: peribili- ary plexus. Scale bars: 100 μm. C: 3-D volume-rendering image of lymphatic vessels and bile ducts in the portal tract with enlarged images (D–F). Scale bar: 100 μm. BDL, bile duct ligation; EC-GFP, Endothelial-specific green fluorescent protein mice; LV, lymphatic vessel.
Article Snippet: The liver slides were washed with PBS and incubated in blocking buffer (PBS containing 5% donkey serum and 0.3% triton X-100) at room temperature for 1 h. After blocking was completed, the liver slides were incubated with goat anti-mouse LYVE1 (1:200, AF2125, R&D Systems, Minneapolis, MN) (17),
Techniques: Imaging, Staining, Ligation
Journal: American journal of physiology. Gastrointestinal and liver physiology
Article Title: An optimized visualization and quantitative protocol for in-depth evaluation of lymphatic vessel architecture in the liver.
doi: 10.1152/ajpgi.00139.2023
Figure Lengend Snippet: Figure 5. A workflow for quantification of lymphatic vessel parameters in 3-D volume images. Cleared liver tissue was stained with LYVE1 (red) for lym- phatic vessels (LVs) and reconstructed three-dimensional (3-D) images of the portal tract in the mouse liver (EC-GFP reporter mouse) were created. The “Surface” rendering tool in Imaris software were used to determine a total volume of LYVE1-positive LVs (A–C), whereas the “Filament Tracer” rendering tool was used for quantification of the diameter and branch number of LVs (D–F). A:LYVE1-positive LVs were captured based on fluorescence intensities. B: thresholds were manually adjusted to determine LVs. C:Rendered LYVE1-positive LVs were visually checked to confirm proper vascular connections. LVs with improper connections and/or speckled background structure were removed manually. D: LYVE1-positive LVs were captured based on fluores- cence intensities using automatic filament and path detection in the “Filament Tracer” rendering tool. E: thresholds were manually adjusted to determine LVs. F: LVs with disconnected and speckled background structures were removed manually. All outputs of LV parameters were exported to Excel files for statistical analysis. EC-GFP, Endothelial-specific green fluorescent protein mice; LV, lymphatic vessel.
Article Snippet: The liver slides were washed with PBS and incubated in blocking buffer (PBS containing 5% donkey serum and 0.3% triton X-100) at room temperature for 1 h. After blocking was completed, the liver slides were incubated with goat anti-mouse LYVE1 (1:200, AF2125, R&D Systems, Minneapolis, MN) (17),
Techniques: Staining, Software
Journal: American journal of physiology. Gastrointestinal and liver physiology
Article Title: An optimized visualization and quantitative protocol for in-depth evaluation of lymphatic vessel architecture in the liver.
doi: 10.1152/ajpgi.00139.2023
Figure Lengend Snippet: Figure 6. Comparison of lymphatic vessel parameters between 3-D volume-rendering images and conventional two-dimensional (2-D) images in normal and biliary fibrotic livers. A, left: reconstructed three-dimensional (3-D) image of the portal tract in the liver from a sham-operated mouse (EC-GFP re- porter mouse). Imaging condition: z-step size ¼ 0.4 μm step, image volume [x] [y] [z] ¼ 777 μm 777 μm 215 μm. Liver tissue was cleared and stained with LYVE1 (red, lymphatic vessel: LV) and aSMA (white, portal vein: PV). Right: 3-D volume-rendering image of lymphatic vessels and portal vein using Imaris software. Scale bars: 100 μm. B, left: reconstructed 3-D image of the portal tract in the liver from a 4-wk BDL mouse (EC-GFP reporter mouse). Imaging condition: z-step size ¼ 0.4 μm, image volume [x] [y] [z] ¼ 793 μm 894 μm 190 μm. Right: 3-D volume-rendering image of lym- phatic vessels and portal vein using Imaris software. Scale bars: 100 μm. C: quantification of lymphatic vessel (LV) parameters (diameter, branch number, and total volume) from 3-D volume-rendering images in sham (n ¼ 4) and 4-wk BDL (n ¼ 3) mouse livers. PT, portal tract; FC, fold change. D: conventional 2-D images of liver tissues (frozen section, 7-lm thickness) from sham and 4-wk BDL mice (EC-GFP reporter mice). Red: LYVE1-positive lymphatic vessel. Scale bars: 100 μm. E: quantification of LV parameters (diameter, number, and total area) from conventional 2-D images in sham (n ¼ 6) and 4-wk BDL (n ¼ 6) mouse livers. BDL, bile duct ligation; EC-GFP, Endothelial-specific green fluorescent protein mice; LV, lymphatic vessel.
Article Snippet: The liver slides were washed with PBS and incubated in blocking buffer (PBS containing 5% donkey serum and 0.3% triton X-100) at room temperature for 1 h. After blocking was completed, the liver slides were incubated with goat anti-mouse LYVE1 (1:200, AF2125, R&D Systems, Minneapolis, MN) (17),
Techniques: Comparison, Imaging, Staining, Software, Ligation
Journal: Genes & Development
Article Title: Mechanotransduction activates canonical Wnt/β-catenin signaling to promote lymphatic vascular patterning and the development of lymphatic and lymphovenous valves
doi: 10.1101/gad.282400.116
Figure Lengend Snippet: β-Catenin is necessary for the development of LVVs, LVs, VVs, and cardiac valves. ( A – J ) The gene encoding β-catenin ( Ctnnb1 ) was deleted from LECs, LVV-ECs, LV-ECs, and VV-ECs using Lyve1-Cre mice . IHC was performed for the indicated markers. Frontal sections from E14.5 ( A – D ) and E16.5 ( G , H ) embryos revealed the LVVs in controls (arrows) but not in their Lyve1-Cre; Ctnnb1 LOF littermates. Arrowheads point to the valve-forming area of mutants. ( G , H ) At E16.5, VVs are seen in control embryos (yellow arrows) but not in mutants. ( E , F ) SEM confirmed the presence of LVV-ECs (magenta) and VV-ECs (green) in E14.5 control embryos and their absence in Lyve1-Cre;Ctnnb1 LOF littermates. ( I , J ) Whole-mount IHC of the mesenteric lymphatic vessels revealed the presence of LVs in E18.5 control (arrows) but not Lyve1-Cre;Ctnnb1 LOF littermates. ( I ) Furthermore, PROX1 is strongly expressed in the LVs but down-regulated elsewhere in the lymphatic vessels of controls. ( J ) In contrast, PROX1 expression is uniformly high in the lymphatic vessels of the mutants. ( K , L ) Prox1 +/ Cre was used to delete Ctnnb1 from the PROX1 + cells of the cardiac semilunar valves. IHC was performed for the indicated markers. E13.5 Prox1 +/ Cre ; Ctnnb1 LOF embryos lacked the PROX1 + FOXC2 + cells of the cardiac valves (arrows). (LS) Lymph sacs; (IJV) internal jugular vein; (SCV) subclavian vein; (SVC) superior vena cava. Bars: A – J , 200 µm; K , L , 100 µm. n = 4 for each experiment.
Article Snippet: Primary antibodies used for immunostaining were as follows: rabbit anti-PROX1 (AngioBio), goat anti-human PROX1 (R&D Systems), sheep anti-mouse FOXC2 (R&D Systems), goat anti-mouse VEGFR3 (R&D Systems),
Techniques: Control, Expressing
Journal: Genes & Development
Article Title: Mechanotransduction activates canonical Wnt/β-catenin signaling to promote lymphatic vascular patterning and the development of lymphatic and lymphovenous valves
doi: 10.1101/gad.282400.116
Figure Lengend Snippet: β-Catenin is necessary for the patterning of lymphatic vessels. ( A – G ) E17.5 and E14.5 Lyve1-Cre;Ctnnb1 LOF and its control littermates were harvested, and the lymphatic vessels of dorsal skin were analyzed by whole-mount IHC for the indicated markers. ( A , B ) The lymphatic vessels of control embryos have reached and crossed over the midline (red dotted line) to form a network of vessels. In contrast, the lymphatic vessels of the mutants are dilated and have not reached the midline. Additionally, abnormal recruitment of α-SMA + mural cells is visible in the lymphatic vessels of mutants. The lymphatic vessel diameter is quantified in C . ( D , E ) The lymphatic vessels at the leading edge are thin and elongated in E14.5 control embryos. In contrast, they are dilated in Lyve1-Cre;Ctnnb1 LOF embryos. D ′ and E ′ show NRP2 expression alone from the corresponding pictures in D and E , respectively. NRP2 clearly labels the filopodia (red asterisks) on the tip cells of the growing lymphatic vessels. The length ( F ) and the number ( G ) of filapodia are significantly reduced in the mutant embryos. Bars: A , B , 500 µm; D – E ′, 50 µm. n = 4 for each experiment. (**) P < 0.01.
Article Snippet: Primary antibodies used for immunostaining were as follows: rabbit anti-PROX1 (AngioBio), goat anti-human PROX1 (R&D Systems), sheep anti-mouse FOXC2 (R&D Systems), goat anti-mouse VEGFR3 (R&D Systems),
Techniques: Control, Expressing, Mutagenesis
Journal: Genes & Development
Article Title: Mechanotransduction activates canonical Wnt/β-catenin signaling to promote lymphatic vascular patterning and the development of lymphatic and lymphovenous valves
doi: 10.1101/gad.282400.116
Figure Lengend Snippet: The Wnt/β-catenin signaling pathway regulates FOXC2 expression in LECs. ( A – D ) The dorsal skin of E15.5 control ( A , B ) and Lyve1-Cre;Ctnnb1 LOF ( C , D ) embryos was analyzed by whole-mount IHC for the indicated markers. FOXC2 is expressed in both the tip ( A , A ′, arrows) and collecting lymphatic vessels ( B , B ′, arrows) of control embryos. ( B , B ′) Rudimentary LVs are enriched for FOXC2 (arrowhead). ( C , C ′) FOXC2 expression is dramatically down-regulated in the tip cells (arrows) of mutants. ( D , D ′) A modest down-regulation of FOXC2 expression is observed in the collecting lymphatic vessels of mice lacking β-catenin (arrows). Furthermore, LV rudiments are absent in Lyve1-Cre;Ctnnb1 LOF embryos. ( E – G ) The lymphatic vessels of the skin from E16.5 control and Foxc2 −/− littermates were analyzed by IHC using the indicated markers. The magenta lines indicate the distance between the tip cells and the opposing front. ( G ) This distance is significantly increased in Foxc2 −/− embryos, indicating lymphatic vascular hypoplasia. The diameter of lymphatic vessels is also significantly increased in Foxc2 −/− embryos. ( H – J ) The tip cells of E15.5 control embryos have numerous well-formed filopodia (red dots). In contrast, the tip cells of Foxc2 −/− embryos have a bulbous architecture and hardly any filopodia. The number and length of filopodia in control and Foxc2 −/− embryos are quantified in J . Bars: A – D , 100 µm; E , F , 500 µm; H , I , 25 µm. n = 4 for each experiment. (**) P < 0.01; (***) P < 0.001.
Article Snippet: Primary antibodies used for immunostaining were as follows: rabbit anti-PROX1 (AngioBio), goat anti-human PROX1 (R&D Systems), sheep anti-mouse FOXC2 (R&D Systems), goat anti-mouse VEGFR3 (R&D Systems),
Techniques: Expressing, Control
Journal: Genes & Development
Article Title: Mechanotransduction activates canonical Wnt/β-catenin signaling to promote lymphatic vascular patterning and the development of lymphatic and lymphovenous valves
doi: 10.1101/gad.282400.116
Figure Lengend Snippet: FOXC2 compensates for the loss of β-catenin to regulate lymphatic vessel patterning. ( A – E ) Primary human LECs were infected with control or FOXC2-expressing retroviral particles. Scratch assay was performed 24 h later in the presence or absence of 25 µM iCRT3. The space between the red dotted lines indicates the open scratch wound. ( E ) The wound size was measured at various time points and plotted. iCRT3 significantly inhibits the ability of control LECs to “heal” the scratch wound. FOXC2-overexpressing cells are able to significantly overcome iCRT3-induced inhibition. ( F – I ) The lymphatic vessels of the dorsal skin of E16.5 control ( F ), Lyve1-Cre;Ctnnb1 LOF ( G ), Lyve1-Cre;Ctnnb1 LOF ;FOXC2 GOF ( H ), and Lyve1-Cre ;FOXC2 GOF ( I ) embryos were analyzed by IHC for VEGFR3. ( J ) The diameter of the vessels and the distance between the tip cells of the opposing fronts were quantified ( Supplemental Fig. 7E–H ) and plotted. In comparison with control embryos, the lymphatic vessels of Lyve1-Cre;Cttnb1 LOF embryos are significantly dilated. The distance between the migrating fronts is also significantly increased, indicating lymphatic vascular hypoplasia. Ectopic expression of FOXC2 significantly rescues these defects. ( K – N ) Coimmunohistochemistry for the indicated markers revealed the presence of α-SMA + mural cells on the VEGFR3 + lymphatic vessels of Lyve1-Cre;Cttnb1 LOF embryos (shown in L ). ( M ) This defect is fully rescued by ectopic expression of FOXC2. Lower magnification pictures of F – I and K – N are presented in Supplemental Figure 7 . ( O – R ) The mesenteric lymphatic vessels of E17.5 embryos were analyzed by IHC for the indicated markers. Dilation of lymphatic vessels and the abnormal recruitment of α-SMA + mural cells caused by the loss of β-catenin were rescued by FOXC2 overexpression. LVs are seen in control (arrow) but not in any of the mutant embryos. ( S ) Model for the relationship between OSS, β-catenin, FOXC2, and PROX1 during lymphatic vascular development. We did not exclude the role of yet to be identified Wnt ligands that function independently or in cooperation with OSS to activate β-catenin. Bars, 100 µm. ( A – E ) n = 3. ( F – R ) n = 4. (*) P < 0.05; (**) P < 0.01; (***) P < 0.001.
Article Snippet: Primary antibodies used for immunostaining were as follows: rabbit anti-PROX1 (AngioBio), goat anti-human PROX1 (R&D Systems), sheep anti-mouse FOXC2 (R&D Systems), goat anti-mouse VEGFR3 (R&D Systems),
Techniques: Infection, Control, Expressing, Retroviral, Wound Healing Assay, Inhibition, Comparison, Over Expression, Mutagenesis
Journal: eLife
Article Title: EphrinB2-EphB4 signalling provides Rho-mediated homeostatic control of lymphatic endothelial cell junction integrity
doi: 10.7554/eLife.57732
Figure Lengend Snippet: ( A ) Experimental scheme for Ephb4 deletion in the mature vasculature by three consecutive intraperitoneal (i.p.) 4-OHT injections (arrowheads) into 3-week-old Ephb4 flox ;R26-mTmG;Pdgfb-CreER T2 mice. Ear skin whole-mount immunofluorescence from 7-week-old Ephb4 mice using antibodies against VE-cadherin (green) and LYVE1 (red) or GFP (single channel images). GFP expression demonstrates Cre recombination in arteries (A), veins (V) and LYVE1 - collecting lymphatic vessels (Lcol), but not LYVE1 + lymphatic capillaries (Lcap) in control ear. Mutant collecting vessels show abnormal LYVE1 expression. ( B ) Ear skin whole-mount immunofluorescence of 7-week-old Ephb4 mice using an antibody against VE-cadherin. Note altered morphology of collecting lymphatic vessel junctions (arrow) in Ephb4 mutant compared to heterozygous littermates. ( C ) Experimental scheme for Efnb2 deletion in the mature vasculature by 3 consecutive 4-OHT injections (arrowheads) into 3-week-old Efnb2 flox ;Pdgfb-CreER T2 mice. Ear skin whole-mount immunofluorescence of 5-week-old Efnb2 mice using antibodies against VE-cadherin (green) and LYVE1 (red). ( D ) Ear skin whole-mount immunofluorescence of 5-week-old Efnb2 mice using an antibody against VE-cadherin. Note altered morphology of collecting lymphatic vessel junctions (arrow) in Efnb2 mutant compared to Cre negative littermates already after 2 weeks of Cre induction. ( E ) In vivo basal permeability assay in skin and lung of 5-week-old Efnb2 mutants and Cre negative littermates. Data represent mean ± s.e.m. (n = 6–7 mice from two independent experiments). Efnb2 deletion does not impact on basal barrier function of skin and lung blood vasculature. ( F ) Experimental scheme for Efnb2 deletion using the Cdh5-CreER T2 line and three consecutive tamoxifen injections (arrowheads). Vascular leakage in the skin of 5-week-old Efnb2 mutants and Cre negative littermates was induced with VEGF or histamine. Note, endothelial deletion of Efnb2 does not impact on junctional regulation in leakage-induced dermal blood vasculature. Data represent mean ± s.e.m. (n = 7-8 mice from two independent experiments). Western blot from total lung lysates 8 days after the first tamoxifen administration showing depletion of EphrinB2 in Cre + mice. VE-cadherin was used as a loading control. Source data for panels ( E,F ) are provided. Scale bars: 100 μm ( A,C ), 10 μm ( B,D ). Figure 1—source data 1. Flow cytometric analysis of endothelial cell proliferation in postnatal mouse ear skin.
Article Snippet: Antibody ,
Techniques: Immunofluorescence, Expressing, Control, Mutagenesis, In Vivo, Permeability, Western Blot
Journal: eLife
Article Title: EphrinB2-EphB4 signalling provides Rho-mediated homeostatic control of lymphatic endothelial cell junction integrity
doi: 10.7554/eLife.57732
Figure Lengend Snippet:
Article Snippet: Antibody ,
Techniques: Mutagenesis, Isolation, Sequencing, Negative Control, Recombinant, Activation Assay